[1]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[2]
|
Lehmann, B.D., et al. (2011) Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. Journal of Clinical Investigation, 121, 2750-2767. https://doi.org/10.1172/JCI45014
|
[3]
|
Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.E5.
|
[4]
|
段懿珊, 郝凯峰. 早期三阴性乳腺癌保乳手术治疗的临床效果[J]. 深圳中西医结合杂志, 2023, 33(11): 91-94.
|
[5]
|
Untch, M., Jackisch, C., Schnesswei, A., et al. (2015) A Randomized Phase Ⅲ Trial Comparing Neoadjuvant Chemotherapy with Weekly Nanoparticle-Based Paclitaxel with Solvent-Based Paclitaxel Followed by Anthracyline/Cyclophosphamide for Patients with Early Breast Cancer (GeparSepto); GBG 69. Cancer Research, 75, S2-07. https://doi.org/10.1158/1538-7445.SABCS14-S2-07
|
[6]
|
曹志宇, 张庆军, 吴有军, 等. 早期三阴性乳腺癌保乳手术治疗的临床效果[J]. 解放军医学杂志, 2020, 45(9): 986-989.
|
[7]
|
翟睿, 齐晶, 马晓霞. 三阴性乳腺癌患者采取保乳手术治疗的临床效果及5年随访观察分析[J]. 河北医学, 2023, 29(10): 1677-1682.
|
[8]
|
Offersen, B.V., Alsner, J., Nielsen, H.M., et al. (2020) Hypofractionated versus Standard Fractionated Radiotherapy in Patients with Early Breast Cancer or Ductal Carcinoma in Situ in a Randomized Phase Ⅲ Trial: The DBCG HYPO Trial. Journal of Clinical Oncology, 38, 3615-3625. https://doi.org/10.1200/JCO.20.01363
|
[9]
|
Kundranda, M.N. and Niu, J. (2015) Albumin-Bound Paclitaxel in Solid Tumors: Clinical Development and Future Directions. Drug Design, Development and Therapy, 9, 3767-3777. https://doi.org/10.2147/DDDT.S88023
|
[10]
|
Bauer, J.A., et al. (2010) Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation. Clinical Cancer Research, 16, 681-690. https://doi.org/10.1158/1078-0432.CCR-09-1091
|
[11]
|
Juul, N., et al. (2010) Assessment of an RNA Interference Screen-Derived Mitotic and Ceramide Pathway Metagene as a Predictor of Response to Neoadjuvant Paclitaxel for Primary Triple-Negative Breast Cancer: A Retrospective Analysis of Five Clinical Trials. The Lancet Oncology, 11, 358-365. https://doi.org/10.1016/S1470-2045(10)70018-8
|
[12]
|
Trudeau, M., et al. (2005) Selection of Adjuvant Chemotherapy for Treatment of Node-Positive Breast Cancer. The Lancet Oncology, 6, 886-898. https://doi.org/10.1016/S1470-2045(05)70424-1
|
[13]
|
Henderson, I.C., et al. (2003) Improved Outcomes from Adding Sequential Paclitaxel But Not from Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients with Node-Positive Primary Breast Cancer. Journal of Clinical Oncology, 21, 976-983. https://doi.org/10.1200/JCO.2003.02.063
|
[14]
|
Levine, M.N., et al. (2005) Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil with Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women with Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. Journal of Clinical Oncology, 23, 5166-5170. https://doi.org/10.1200/JCO.2005.09.423
|
[15]
|
Bonneterre, J., et al. (2005) Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients with Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial. Journal of Clinical Oncology, 23, 2686-2693. https://doi.org/10.1200/JCO.2005.05.059
|
[16]
|
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials. The Lancet, 365, 1687-1717. https://doi.org/10.1016/S0140-6736(05)66544-0
|
[17]
|
Yin, L., Duan, J.J., Bian, X.W. and Yu, S.C. (2020) Triple-Negative Breast Cancer Molecular Subtyping and Treatment Progress. Breast Cancer Research, 22, Article No. 61. https://doi.org/10.1186/s13058-020-01296-5
|
[18]
|
徐硕, 金鹏飞, 徐文峰, 等. 环磷酰胺分析方法的研究进展[J]. 西北药学杂志, 2023, 38(2): 223-226.
|
[19]
|
Nakatsukasa, K., et al. (2017) Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in HER2-Negative Primary Breast Cancer. Breast Cancer, 24, 63-68. https://doi.org/10.1007/s12282-016-0666-7
|
[20]
|
Wu, C.E., et al. (2014) Identification of Patients with Node-Negative, Triple-Negative Breast Cancer Who Benefit from Adjuvant Cyclophosphamide, Methotrexate, and 5-Fluorouracil Chemotherapy. Anticancer Research, 34, 1301-1306.
|
[21]
|
康一坤, 袁芃. 《铂类药物晚期乳腺癌应用专家共识(2020版)》解读[J]. 中国肿瘤临床, 2022, 49(6): 271-274.
|
[22]
|
Loibl, S., O’Shaughnessy, J., Untch, M., et al. (2018) Addition of the PARP Inhibitor Veliparib plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial. The Lancet Oncology, 19, 497-509. https://doi.org/10.1016/S1470-2045(18)30111-6
|
[23]
|
Von Minckwitz, G., et al. (2014) Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): Arandomised Phase 2 Trial. The Lancet Oncology, 15, 747-756. https://doi.org/10.1016/S1470-2045(14)70160-3
|
[24]
|
Jovanovic, B., et al. (2017) A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel with or without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-Term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical Cancer Research, 23, 4035-4045. https://doi.org/10.1158/1078-0432.CCR-16-3055
|
[25]
|
Li, Q., Li, Q., Zhang, P., et al. (2015) A Phase II Study of Capecitabine Plus Cisplatin in Metastatic Triple-Negative Breast Cancer Patients Pretreated with Anthracyclines and Taxanes. Cancer Biology & Therapy, 16, 1746-1753. https://doi.org/10.1080/15384047.2015.1095400
|
[26]
|
Heeke, A.L. and Tan, A.R. (2021) Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer. Cancer and Metastasis Reviews, 40, 537-547. https://doi.org/10.1007/s10555-021-09972-4
|
[27]
|
Leon-Ferre, R.A. and Goetz, M.P. (2023) Advances in Systemic Therapies for Triple Negative Breast Cancer. BMJ, 381, e071674. https://doi.org/10.1136/bmj-2022-071674
|
[28]
|
Zhu, Y., Zhu, X., Tang, C., et al. (2021) Progress and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1876, Article ID: 188593. https://doi.org/10.1016/j.bbcan.2021.188593
|
[29]
|
Liu, J., Wang, Y., Tian, Z., et al. (2022) Multicenter Phase II Trial of Camrelizumab Combined with Apatinib and Eribulin in Heavily Pretreated Patients with Advanced Triple-Negative Breast Cancer. Nature Communications, 13, Article No. 3011. https://doi.org/10.1038/s41467-022-30569-0
|
[30]
|
Peng, Z., Su, P., Yang, Y., et al. (2020) Identification of CTLA-4 Associated with Tumor Microenvironment and Competing Interactions in Triple Negative Breast Cancer by Co-Expression Network Analysis. Journal of Cancer, 11, 6365-6375. https://doi.org/10.7150/jca.46301
|
[31]
|
Kaewkangsadan, V., Verma, C., Eremin, J.M., et al. (2018) Tumour-Draining Axillary Lymph Nodes in Patients with Large and Locally Advanced Breast Cancers Undergoing Neoadjuvant Chemotherapy (NAC): The Crucial Contribution of Immune Cells (Effector, Regulatory) and Cytokines (Th1, Th2) to Immune-Mediated Tumour Cell Death Induced by NAC. BMC Cancer, 18, Article No. 123. https://doi.org/10.1186/s12885-018-4044-z
|
[32]
|
Bernier, C., et al. (2018) DZ-2384 Has A Superior Preclinical Profile to Taxanes for Thetreatment of Triple-Negative Breast Cancer and Is Synergistic with Anti-CTLA-4 Immunotherapy. Anti-Cancer Drugs, 29, 774-785. https://doi.org/10.1097/CAD.0000000000000653
|
[33]
|
Nielsen, T.O., et al. (2004) Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clinical Cancer Research, 10, 5367-5374. https://doi.org/10.1158/1078-0432.CCR-04-0220
|
[34]
|
Livasy, C.A., et al. (2006) Phenotypic Evaluation of the Basal-Like Subtype of Invasive Breast Carcinoma. Modern Pathology, 19, 264-271. https://doi.org/10.1038/modpathol.3800528
|
[35]
|
Cho, S.Y. (2019) Identification of ERBB Pathway-Activated Cells in Triple-Negative Breast Cancer. Genomics & Informatics, 17, e3. https://doi.org/10.5808/GI.2019.17.1.e3
|
[36]
|
Farmer, H., et al. (2005) Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. Nature, 434, 917-921. https://doi.org/10.1038/nature03445
|
[37]
|
Gelmon, K.A., et al. (2011) Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer: A Phase 2, Multicentre, Open-Label, Non-Randomised Study. The Lancet Oncology, 12, 852-861. https://doi.org/10.1016/S1470-2045(11)70214-5
|
[38]
|
Barton, V.N., et al. (2015) Androgen Receptor Biology in Triple Negative Breast Cancer: A Case for Classification as AR or Quadruple Negative Disease. Hormones and Cancer, 6, 206-213. https://doi.org/10.1007/s12672-015-0232-3
|
[39]
|
Gucalp, A., et al. (2013) Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. Clinical Cancer Research, 19, 5505-5512. https://doi.org/10.1158/1078-0432.CCR-12-3327
|
[40]
|
毛丹, 李玲, 胡洋, 等. 中药复方联合化疗治疗IV期三阴性乳腺癌疗效和安全性的系统评价和Meta分析[J]. 中国民族民间医药, 2022, 31(20): 100-108.
|